Publication of change in the total number of shares and votes in Diamyd Medical AB

As of December 2, 2014, the share capital in Diamyd Medical AB (publ) is
2,010,142.3 SEK. The total number

of votes is 2,844,668 and the total number of shares is 19,819,422, divided
among 958,584 shares of series A   (1 vote) and 18,860,838 shares of series B
(1/10 vote).

The change is, as previously announced, due to a direct placement of 100,000 new
series B shares to Protein Sciences Corporation, Inc., due to a signed
agreement. The Board of Diamyd Medical decided on the new issue based on the
authorization given by the Annual General Meeting on November 22, 2013.

About Diamyd Medical
Diamyd Medical is dedicated to fighting type 1 diabetes and to working toward a
cure for the disease. Diamyd Medical’s projects include development of
combination regimens with the GAD-based diabetes vaccine Diamyd® for arresting
the successive destruction of insulin-producing beta cells. Diamyd Medical
licenses exclusive intellectual rights for the GAD molecule from the University
of California. The company also has an exclusive license from the University of
California for therapeutic use of GABA for the treatment of diabetes and other
inflammation-related conditions, including metabolic syndrome and rheumatoid
arthritis.

Diamyd Medical owns 46 percent of the stem cell company Cellaviva AB, which is
establishing a Swedish commercial bank for private family saving of stem cells
in umbilical cord blood and other sources of stem cells. Stem cells are expected
to be used in Personalized Regenerative Medicine (PRM), for example, to restore
beta cell mass in diabetes patients where autoimmunity has been arrested. Diamyd
Medical also has a 10 percent shareholding in the medical technology company
Companion Medical, Inc., based in San Diego, in the US, and a minor shareholding
and other financial interests in the US gene therapy company Periphagen
Holdings, Inc.

Remium Nordic AB is the Company’s Certified Adviser.
For further information, please contact:
Anders Essen-Möller, Chairman Diamyd Medical AB
Phone: +46 70 55 10 679. E-mail: anders.essen-moller@diamyd.com
Diamyd Medical AB (publ)
Kungsgatan 29, SE-111 56 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8
661 63 68
E-mail: info@diamyd.com. Reg. no.: 556242-3797. Website: www.diamyd.com.